NCT00411450View on ClinicalTrials.gov

Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

October 31, 2010

Conditions
Colon CancerColorectal CancerRectal CancerCancerMetastatic CancerMetastatic Colorectal CancerOncology
Interventions
BIOLOGICAL

Panitumumab

Administered by intravenous infusion

DRUG

FOLFIRI

Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00411450 - Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment | Biotech Hunter | Biotech Hunter